Glycomics/Glycobiology Market Trends

Growth Drivers

• Increasing prevalence of chronic diseases: There is a growing burden of chronic diseases, such as cancer and metabolic disorders, which efficiently drives business in the market. In this regard, RKI in 2024 reported that in Germany, nearly 2.5 million patients required glycan-based diagnostics in 2025, which is a 41% rise from 2020. Besides, WHO states that in Europe, there will be a heightened demand for glycotherapeutics by 2030. Therefore, this expanding demand necessitates the requirement for glycomics or glycobiology therapeutics.
   
• Progression in glycomic innovations: The strategic collaborations between pharmaceutical firms and innovations in glycobiology therapeutics are yet another driver in the market. In this regard, in 2023, Thermo Fisher acquired GlycoSelect, which enhanced its product portfolio significantly by capturing an increased market share of 14%. Besides, in 2024, Agilent announced a partnership with 20 EU-based hospitals to introduce AI-based glycomics platforms, which reduce lab costs by 30%, thereby reflecting an increased market adoption.

Manufacturer Strategies Strengthening Glycomics/Glycobiology Market Positions

The global market is gaining traction due to the strategies opted by manufacturers to strengthen their market positions. Key trends undertaken by the firms include market innovation, collaborations, and expansions in rapidly emerging markets. In this regard, the U.S. FDA’s Biosimilars Research Awards highly support the innovation in the biosimilar sector, aiding in cost-effective alternatives, expanding the market reach internationally.  These factors are anticipated to contribute to the market adoption, thereby creating revenue opportunities for global market players.

Revenue Opportunities for Glycomics/Glycobiology Manufacturers

Feasible Expansion Models Shaping the Glycomics/Glycobiology Market

The market is witnessing remarkable growth, critically influenced by different sorts of expansion models undertaken to enhance accessibility and affordability. It is reported that there is a heightened demand for advanced diagnostic tools such as glycomic-based solutions in India’s pharmaceutical sector, due to which it is estimated to reach USD 135 billion by 2030. Furthermore, this robust market ecosystem intends to support glycomic manufacturers, allowing them to collaborate with domestic healthcare facilities, thereby denoting a positive market outlook.

Feasibility Models for Glycomics Market Expansion

Challenge

• Increasing equipment and operational costs: This factor poses a significant challenge for the market upliftment across all nations. The high cost associated with specialized equipment such as mass spectrometers and glycan microarrays hinders expanded access for glycomics researchers. Besides, it is reported that glycomics analysis services can cost between USD 100 to USD 600 per sample, making it challenging for smaller institutions to invest in this sector.